Canine Cancer Research Alliance
- Assets
- $370.9k
- Revenue
- $415.8k
- Investments
- $0.0
- Employees
- 0
- Location
- Bellevue, WA
- Founding
- 06/2018
- Data as of
- 12/2022
- EIN
- 82-3762441
Organization Overview
Canine Cancer Research Alliance, operating under the name Canine Cancer Alliance, is located in Bellevue, WA. The organization was established in 2018. According to its NTEE Classification (D12) the organization is classified as: Fund Raising & Fund Distribution, under the broad grouping of Animal-Related and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Canine Cancer Alliance is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2022, Canine Cancer Alliance generated $415.8k in total revenue. This organization has experienced exceptional growth, as over the past 3 years, it has increased revenue by an average of 55.8% each year . All expenses for the organization totaled $211.9k during the year ending 12/2022. While expenses have increased by 47.1% per year over the past 3 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2022
Describe the Organization's Mission:
Part 3 - Line 1
THE MISSION OF THE CANINE CANCER ALLIANCE IS TO END DOG CANCER AS WE KNOW IT TODAY BY FUNDING AND ADVANCING RESEARCH FOR PREVENTION AND CURES. STUDIES AND CLINICAL TRIALS SUPPORTED BY THE CCA EMPHASIZE THE DISCOVERY AND DEVELOPMENT OF SAFE, EFFECTIVE, AND AFFORDABLE TREATMENTS FOR OUR CANINE FAMILY MEMBERS.
Describe the Organization's Program Activity:
Part 3 - Line 4a
2022 PROGRAM FOCUSED ON CANCER IMMUNOTHERAPY RESEARCH. RESEARCH STUDIES. TWO NEW STUDIES WERE INITIATED: (1)CAR-T THERAPY FOR SARCOMAS (UNIVERSITY OF ILLINOIS WITH NORTHWESTERN UNIVERSITY) (2) IMMUNOTHERAPY FOR TRANSITIONAL CELL CARCINOMA (BLADDER CANCER) AND BRAF MONITORING (NORTH CAROLINA STATE UNIVERSITY). TWO OTHER STUDIES ARE ONGOING: CLINICAL STUDIES IN THERAPEUTIC CANINE CANCER VACCINE TARGETING EGFR/HER2 OVER-EXPRESSING TUMORS (YALE SCHOOL OF MEDICINE) AND NONSPECIFIC CANCER VACCINE IMMUNOTHERAPY. EGFR/HER2 VACCINE CLINICAL TRIAL WAS OPENED IN NOV 2022 AND BEGAN ENROLLING PATIENTS WITH OSTEOSARCOMA, HEMANGIOSARCOMA AND TCC. EDUCATION AND CANCER AWARENESS. WE DEVELOPED AND SHARED INFORMATION INCLUDING VIDEOS TO ADVANCE CANINE CANCER AWARENESS ON OUR WEBSITE AND SOCIAL MEDIA CHANNELS. THE CONTENT INCLUDES DETAILS OF NEW CANCER TREATMENTS INCLUDING CANCER IMMUNOTHERAPY, CLINICAL TRIALS, RECENT RESEARCH RESULTS, AND STRATEGIES FOR REDUCING CANCER RISKS AND EARLY DETECTION.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Mari Maeda Whitaker Director, Officer | OfficerTrustee | 40 | $0 |
Tai Truong Director | Trustee | 0.5 | $0 |
Sri Kumar Director | Trustee | 0.5 | $0 |
Sam Earp Director | Trustee | 0.5 | $0 |
Elizabeth Zuidema Director | Trustee | 0.5 | $0 |
James Gimlett Director | Trustee | 2 | $0 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $413,227 |
| Noncash contributions included in lines 1a–1f | $210,478 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $413,227 |
| Total Program Service Revenue | $0 |
| Investment income | $2,618 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $0 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $415,845 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $183,884 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $0 |
| Pension plan accruals and contributions | $0 |
| Other employee benefits | $0 |
| Payroll taxes | $0 |
| Fees for services: Management | $10,214 |
| Fees for services: Legal | $90 |
| Fees for services: Accounting | $56 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $1,565 |
| Advertising and promotion | $6,880 |
| Office expenses | $491 |
| Information technology | $2,933 |
| Royalties | $0 |
| Occupancy | $0 |
| Travel | $89 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $1,760 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $0 |
| Insurance | $944 |
| All other expenses | $0 |
| Total functional expenses | $211,915 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $0 |
| Savings and temporary cash investments | $370,858 |
| Pledges and grants receivable | $0 |
| Accounts receivable, net | $0 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $0 |
| Net Land, buildings, and equipment | $0 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $0 |
| Total assets | $370,858 |
| Accounts payable and accrued expenses | $0 |
| Grants payable | $0 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $0 |
| Net assets without donor restrictions | $370,858 |
| Net assets with donor restrictions | $0 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $370,858 |
Grants Awarded
Over the last fiscal year, Canine Cancer Research Alliance has awarded $183,884 in support to 4 organizations.
| Grant Recipient | Amount |
|---|---|
YALE UNIVERSITYSCHOOL OF MEDICINE PURPOSE: Research grant to develop safe and effective cancer immunotherapy. Determine the efficacy of EGFR/HER2 canine cancer vaccine through a clinical trial with canine patients. Explore strategies to enhance the patient response rate. | $90,000 |
UNIVERSITY OF ILLINOIS FOUNDATION PURPOSE: The grant is to investigate the safety and efficacy of CAR-T therapy for dogs with aggressive sarcomas. Clinical trial will enrol dogs with hemangiosarcoma, osteosarcoma and recurrent soft tissue sarcoma. | $46,400 |
NORTH CAROLINA UNIVERSITY VETERINARY MEDICAL FOUNDATION PURPOSE: This grant will determine the efficacy of canine cancer immunotherapy treatment for dogs with transitional cell carcinoma (TCC). Patients with bladder cancer with BRAF positive mutation will be enrolled and monitored with molecular tests (urine tests) for cancer progression. | $35,484 |
THERAJAN LLC PURPOSE: This grant supports clinical trial, regulatory approval and commercialization of new canine cancer immunotherapy for dogs with solid tumors. | $12,000 |